... Another drug, Poteligeo (mogamulizumab), is a monoclonal antibody drug, meaning it can specifically recognize certain cell types. It is under investigation and has already been approved by the U.S. Food and Drug Administration for mycosis fungoides and Sezary syndrome. ...
Adult T-Cell Leukemia/Lymphoma (ATLL): Your Guide
... Another drug, Poteligeo (mogamulizumab), is a monoclonal antibody drug, meaning it can specifically recognize certain cell types. It is under investigation and has already been approved by the U.S. Food and Drug Administration for mycosis fungoides and Sezary syndrome. ...
... Monoclonal antibodies include: Mogamulizumab (Poteligeo) — Used to treat two rare forms of non-Hodgkin lymphoma (NHL): Sézary syndrome and mycosis fungoides Obinutuzumab (Gazyva) — Approved for some blood cancers, including follicular lymphoma and chronic lymphocytic leukemia Rituximab (Rituxan) — Approved for CD20-positive NHL and leukemia Tafasitamab-cxix ...
Immunotherapy for Lymphoma: 4 Points To Know
... Monoclonal antibodies include: Mogamulizumab (Poteligeo) — Used to treat two rare forms of non-Hodgkin lymphoma (NHL): Sézary syndrome and mycosis fungoides Obinutuzumab (Gazyva) — Approved for some blood cancers, including follicular lymphoma and chronic lymphocytic leukemia Rituximab (Rituxan) — Approved for CD20-positive NHL and leukemia Tafasitamab-cxix ...